MA44873A - Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative - Google Patents

Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative

Info

Publication number
MA44873A
MA44873A MA044873A MA44873A MA44873A MA 44873 A MA44873 A MA 44873A MA 044873 A MA044873 A MA 044873A MA 44873 A MA44873 A MA 44873A MA 44873 A MA44873 A MA 44873A
Authority
MA
Morocco
Prior art keywords
exsudative
age
treatment
composition
macular degeneration
Prior art date
Application number
MA044873A
Other languages
English (en)
Inventor
Anna P Tretiakova
James M Wilson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MA44873A publication Critical patent/MA44873A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA044873A 2016-04-15 2017-04-14 Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative MA44873A (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662323184P 2016-04-15 2016-04-15
US201662331100P 2016-05-03 2016-05-03
US201762442946P 2017-01-05 2017-01-05
US201762460515P 2017-02-17 2017-02-17
US201762466721P 2017-03-03 2017-03-03

Publications (1)

Publication Number Publication Date
MA44873A true MA44873A (fr) 2019-03-13

Family

ID=59253994

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044873A MA44873A (fr) 2016-04-15 2017-04-14 Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative

Country Status (10)

Country Link
US (2) US11197937B2 (fr)
EP (1) EP3452103A1 (fr)
JP (4) JP7046828B2 (fr)
KR (2) KR102574810B1 (fr)
AU (2) AU2017248731B2 (fr)
CA (1) CA3019426A1 (fr)
IL (2) IL322403A (fr)
MA (1) MA44873A (fr)
SG (2) SG11201808426XA (fr)
WO (1) WO2017180936A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
IL322403A (en) * 2016-04-15 2025-09-01 Univ Pennsylvania Preparations for the treatment of wet age-related macular degeneration
JP7685833B2 (ja) * 2017-09-27 2025-05-30 レジェンクスバイオ インコーポレーテッド 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療
CA3079565A1 (fr) * 2017-10-18 2019-04-25 Regenxbio Inc. Traitement de maladies oculaires et d'un cancer du colon metastatique avec un piege a vegf avec modification post-traductionnelle humain
FI3717636T3 (fi) * 2017-11-27 2023-06-01 4D Molecular Therapeutics Inc Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä
BR112020012336A2 (pt) * 2017-12-19 2021-03-30 Akouos, Inc. Administração de anticorpos terapêuticos mediada por aav para o ouvido interno
US12558434B2 (en) * 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
JP2022049718A (ja) * 2019-02-05 2022-03-30 アステラス製薬株式会社 アデノ随伴ウイルスを用いたｃｘ３ｃｌ１遺伝子の導入による網膜変性疾患の治療
EP3946467A1 (fr) * 2019-04-03 2022-02-09 REGENXBIO Inc. Thérapie génique pour pathologies de l'?il
WO2020219868A1 (fr) * 2019-04-24 2020-10-29 Regenxbio Inc. Agents thérapeutiques à base d'anticorps entièrement humains à modification post-traductionnelle
US20220227875A1 (en) * 2019-05-31 2022-07-21 University Of Florida Research Foundation, Incorporated Vector-based therapy for thyroid disease
KR20250051157A (ko) 2019-06-05 2025-04-16 리제너론 파아마슈티컬스, 인크. 정밀 투여량 전달을 위한 디바이스 및 방법
CN114502197A (zh) * 2019-08-26 2022-05-13 再生生物股份有限公司 用全人经翻译后修饰的抗VEGF Fab治疗糖尿病性视网膜病变
US20240108669A1 (en) * 2019-10-07 2024-04-04 Regenxbio Inc. Adeno-associated virus vector pharmaceutical composition and methods
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021231491A1 (fr) * 2020-05-11 2021-11-18 University Of Florida Research Foundation, Incorporated Correction de maladie par administration de vecteurs aav8 exprimant une naglu à codon optimisé
BR112022021786A2 (pt) * 2020-05-12 2023-01-17 Univ Pennsylvania Composições úteis em tratamento de doença de krabbe
WO2021255589A1 (fr) * 2020-06-16 2021-12-23 Intas Pharmaceuticals Ltd. Vecteur de virus adéno-associé (vaa) scfab anti-vegf et ses utilisations
WO2021255590A1 (fr) * 2020-06-16 2021-12-23 Intas Pharmaceuticals Ltd. Vecteur de virus adéno-associé (aav) anti-vegf et ses utilisations
CN113952473A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
MX2023004377A (es) * 2020-10-16 2023-06-28 Gyroscope Therapeutics Ltd Acido nucleico que codifica una entidad anti-vegf y un regulador del complemento negativo y sus usos para el tratamiento de la degeneracion macular relacionada con la edad.
TW202233841A (zh) * 2020-10-28 2022-09-01 美商銳進科斯生物股份有限公司 用於眼適應症之載體化抗ＴＮＦ－α抗體
CN116457373A (zh) * 2020-10-29 2023-07-18 再生生物股份有限公司 用于眼部适应症的载体化TNF-α拮抗剂
AU2021391433A1 (en) * 2020-12-01 2023-06-22 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
EP4284335A1 (fr) 2021-02-01 2023-12-06 RegenxBio Inc. Thérapie génique de céroïdes-lipofuscinoses neuronales
CA3243517A1 (fr) * 2022-02-02 2023-08-10 Akouos, Inc. Constructions d'anticorps anti-vegf et méthodes connexes pour le traitement de symptômes associés au neurinome de l'acoustique
CA3247507A1 (fr) 2022-04-06 2023-10-12 Regenxbio Inc. Composition pharmaceutique comprenant un vecteur de virus adéno-associé (vaa) recombinant avec une cassette d'expression codant un transgène pour administration suprachoroïdienne
US20260034250A1 (en) 2022-09-30 2026-02-05 Regenxbio Inc. Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
WO2025073297A1 (fr) * 2023-10-06 2025-04-10 甘李药业股份有限公司 Vecteur de virus aav exprimant une protéine de fusion anti-vegf et utilisation de vecteur de virus aav
WO2025160405A1 (fr) * 2024-01-24 2025-07-31 Duke University Compositions et procédés de génération et de sécrétion de particules d'aav

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI953812A0 (fi) 1993-02-12 1995-08-11 Univ Leland Stanford Junior Kohdistettujen geenien säädelty transkriptio ja muita biologisia toimintoja
WO1996020951A1 (fr) 1994-12-29 1996-07-11 Massachusetts Institute Of Technology Proteines chimeres de liaison d'adn
CA2219080A1 (fr) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Regulation d'evenements biologiques fondee sur la rapamycine
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US6117680A (en) 1997-08-26 2000-09-12 Ariad Gene Therapeutics, Inc. Compositions and methods for regulation of transcription
JP2001514007A (ja) 1997-08-27 2001-09-11 アリアド ジーン セラピューティクス インコーポレイテッド キメラ転写アクチベーター、ならびにそれに関連する組成物および使用
AU755784B2 (en) 1998-01-15 2002-12-19 Ariad Pharmaceuticals, Inc. Regulation of biological events using multimeric chimeric proteins
EP1053241A1 (fr) 1998-02-13 2000-11-22 President And Fellows Of Harvard College Agents de dimerisation, production et utilisation
ATE403715T1 (de) 1999-08-09 2008-08-15 Targeted Genetics Corp Erhöhung der expression einer einzelsträngigen, heterologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
EP1224309A2 (fr) 1999-10-21 2002-07-24 Monsanto Company Modification post-traductionnelle de proteines de recombinaison produites dans les plantes
GB2362884A (en) 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
CN1461342A (zh) 2000-07-26 2003-12-10 路德维格癌症研究所 糖基化vegf－b和增加可溶性vegf－b量的方法
CN103555677B (zh) 2001-11-13 2018-01-30 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
WO2003052051A2 (fr) 2001-12-17 2003-06-26 The Trustees Of The University Of Pennsylvania Sequences du serotype 8 du virus associe a l'adenovirus (aav), vecteurs les contenant et utilisations correspondantes
WO2003068801A2 (fr) 2002-02-11 2003-08-21 Genentech, Inc. Variantes d'anticorps a vitesses d'association d'antigene accelerees
US20040208847A1 (en) 2003-03-28 2004-10-21 Fabienne Rolling Method and vectors for selectively transducing retinal pigment epithelium cells
DK3211085T3 (da) 2003-09-30 2021-06-21 Univ Pennsylvania Klader af adeno-associeret virus (aav), sekvenser, vektorer indeholdende disse og anvendelser deraf
US8999678B2 (en) 2005-04-07 2015-04-07 The Trustees Of The University Of Pennsylvania Method of increasing the function of an AAV vector
US7456683B2 (en) 2005-06-09 2008-11-25 Panasonic Corporation Amplitude error compensating device and quadrature skew error compensating device
BRPI0817182A2 (pt) 2007-10-30 2015-03-17 Genentech Inc Método para purificar um anticorpo e composições
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
KR101010352B1 (ko) 2008-05-30 2011-01-25 삼성중공업 주식회사 전력 제어 장치 및 방법
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
WO2010138263A2 (fr) 2009-05-28 2010-12-02 University Of Massachusetts Nouveaux virus adéno-associés (aav) et leurs utilisations
TWI510248B (zh) 2009-06-17 2015-12-01 Abbvie Biotherapeutics Inc 抗－ｖｅｇｆ抗體及其用途
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
EP2634253B1 (fr) 2010-10-27 2016-05-11 Jichi Medical University Virions de virus adéno-associé pour le transfert de gènes dans des cellules neuronales
JP6042825B2 (ja) 2011-02-10 2016-12-14 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法
JP6091435B2 (ja) * 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
DK4005603T3 (da) 2011-04-22 2024-11-25 Univ California Adeno-associerede virus-virioner med variant kapsid og fremgangsmåder til anvendelse heraf
EP2559443A1 (fr) 2011-08-16 2013-02-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et composition pharmaceutiques pour le traitement d'une maladie oculaire chez un sujet
US9169299B2 (en) 2011-08-24 2015-10-27 The Board Of Trustees Of The Leleand Stanford Junior University AAV capsid proteins for nucleic acid transfer
US20130090375A1 (en) * 2011-10-06 2013-04-11 Cornell University Virus-mediated delivery of bevacizumab for therapeutic applications
WO2013170078A1 (fr) 2012-05-09 2013-11-14 Oregon Health & Science University Plasmides et vecteurs viraux associés à un adénovirus
TWI702955B (zh) 2012-05-15 2020-09-01 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒（ａａｖ）ｓｆｌｔ-１治療老年性黃斑部退化（ａｍｄ）
SG11201503637SA (en) 2012-11-08 2015-06-29 Clearside Biomedical Inc Methods and devices for the treatment of ocular diseases in human subjects
US20140154255A1 (en) * 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US9567376B2 (en) 2013-02-08 2017-02-14 The Trustees Of The University Of Pennsylvania Enhanced AAV-mediated gene transfer for retinal therapies
EP2970946A4 (fr) 2013-03-13 2016-09-07 Philadelphia Children Hospital Vecteurs viraux adéno-associés et méthodes d'utilisation associées
SG10201707319UA (en) * 2013-03-15 2017-10-30 Univ Pennsylvania Compositions and methods for treating mpsi
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
ES2857751T3 (es) 2013-10-11 2021-09-29 Massachusetts Eye & Ear Infirmary Métodos para predecir secuencias de virus ancestrales y usos de los mismos
DK3077519T3 (en) 2013-12-03 2021-06-14 Hookipa Biotech Gmbh Cmv-vacciner
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
US11555059B2 (en) 2014-04-25 2023-01-17 The Trustees Of The University Of Pennsylvania LDLR variants and their use in compositions for reducing cholesterol levels
WO2015164757A1 (fr) 2014-04-25 2015-10-29 Oregon Health & Science University Procedes de cartographie d'epitopes d'anticorps de neutralisation virale
DK3142750T3 (da) * 2014-05-13 2020-09-14 Univ Pennsylvania Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf
WO2015191508A1 (fr) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Capsides chimériques
US9840553B2 (en) * 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10064752B2 (en) 2014-09-11 2018-09-04 Orbit Biomedical Limited Motorized suprachoroidal injection of therapeutic agent
CN108347932B (zh) 2015-02-20 2022-09-13 衣阿华大学研究基金会 用于治疗遗传性眼病的方法和组合物
US11535665B2 (en) * 2015-05-13 2022-12-27 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
CA2995849A1 (fr) 2015-08-31 2017-03-09 The Trustees Of The University Of Pennsylvania Vecteur chimerique aav anti-vegf pour le traitement de cancers chez les canines
GB201519086D0 (en) 2015-10-28 2015-12-09 Syncona Partners Llp Gene Therapy
CN108778330A (zh) 2016-01-08 2018-11-09 科尼尔赛德生物医学公司 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置
SG10202008378UA (en) 2016-04-15 2020-10-29 Regenxbio Inc Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
IL322403A (en) * 2016-04-15 2025-09-01 Univ Pennsylvania Preparations for the treatment of wet age-related macular degeneration
JP7685833B2 (ja) 2017-09-27 2025-05-30 レジェンクスバイオ インコーポレーテッド 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療
EP3946467A1 (fr) 2019-04-03 2022-02-09 REGENXBIO Inc. Thérapie génique pour pathologies de l'?il

Also Published As

Publication number Publication date
SG11201808426XA (en) 2018-10-30
KR102920104B1 (ko) 2026-02-02
US11197937B2 (en) 2021-12-14
KR20190031196A (ko) 2019-03-25
CA3019426A1 (fr) 2017-10-19
JP2022141856A (ja) 2022-09-29
JP7111924B2 (ja) 2022-08-02
AU2024216307A1 (en) 2024-10-17
KR102574810B1 (ko) 2023-09-08
NZ746729A (en) 2023-08-25
JP7046828B2 (ja) 2022-04-04
AU2017248731A1 (en) 2018-10-18
IL262207A (en) 2018-11-29
IL262207B1 (en) 2025-09-01
IL322403A (en) 2025-09-01
US20220288238A1 (en) 2022-09-15
JP2019518427A (ja) 2019-07-04
KR20230130765A (ko) 2023-09-12
WO2017180936A1 (fr) 2017-10-19
JP2024105617A (ja) 2024-08-06
AU2017248731B2 (en) 2024-08-29
US20190381194A1 (en) 2019-12-19
SG10201913159UA (en) 2020-02-27
EP3452103A1 (fr) 2019-03-13
JP2022084809A (ja) 2022-06-07
IL262207B2 (en) 2026-01-01
JP7492556B2 (ja) 2024-05-29

Similar Documents

Publication Publication Date Title
MA44873A (fr) Composition pour le traitement de la dégénérescence maculaire liée a l'âge exsudative
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
IL269378A (en) Optimal antibody preparations for the treatment of ocular disorders
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
EP3400010A4 (fr) Combinaisons anti-her2 pour le traitement des tumeurs
EP3380200A4 (fr) Compositions pour le traitement des cheveux
MA42999A (fr) Polythérapie pour le traitement de malignités
MA41041A (fr) Dérivés de benzothiazole substitués utilisés en tant qu'agonistes de gpr40 pour le traitement du diabète de type ii
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
EP3380063A4 (fr) Compositions pour le traitement des cheveux
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension
EP3503883A4 (fr) Composés apparentés à l'entacapone pour traiter la dégénérescence maculaire
EP3716966A4 (fr) Compositions d'alpha-cétoacides pour le traitement de l'hypoalbuminémie
EP3773221A4 (fr) Traitement pour l'hydrocéphalie
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
EP3522865A4 (fr) Méthodes et compositions pour le traitement de vergetures
EP3368048A4 (fr) Méthodes et compositions pour le traitement de l'amyloïdose
MA45552A (fr) Compositions destinées au traitement de l'amylose
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire
EP3373922A4 (fr) Compositions et méthodes pour le traitement de l'homocystinurie